Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions for cellular electrophysiology and maintenance of acid-base balance; dextrose provides caloric support; sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolarity.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion. Adult dose is 1000-2000 mL per 24 hours, providing 20-40 mEq potassium, 100-200 g dextrose, and 77-154 mEq sodium. Rate not exceeding 10 mEq/hour potassium. Adjust based on serum electrolytes and fluid status.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Potassium: terminal half-life ~12-18 hours in normal renal function; clinically, doses may need adjustment in renal impairment due to prolonged elimination
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Potassium: renal >90% (urine), fecals ~10%; chloride: renal >95% (urine); dextrose: fully metabolized to CO2 and water; sodium: renal >98% (urine)
Category C
Category A/B
Electrolyte
Electrolyte